Evidence map›Paper›PMID 40501447›Full record

Trial reportFuture oncology (London, England)2025

A randomized comparative study on maintenance gemcitabine versus supportive care in pleural mesothelioma.

Abanoub Samir Karam, Sherif Abdelwahab, Mai Mohamed Ali Ezz El Din, Mohamed Osama Alorabi

Registry-linked trialAbstract readRandomized Controlled TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05660616 (Switch-Maintenance Gemcitabine After First-Line Chemotherapy), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05660616 phase2completednot on this map

Switch-Maintenance Gemcitabine After First-Line Chemotherapy (Pemetrexed-Platinum) In Patients With Malignant Pleural Mesothelioma In Ain Shams University Hospitals

TypeinterventionalSponsorAin Shams UniversityRan2023 to 2024Enrolled40ConditionsMalignant Pleural MesotheliomaArmsGemcitabine, supportive care
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Pleural mesothelioma.Nature reviews. Disease primers · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Abanoub Samir KaramDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Sherif AbdelwahabDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Mai Mohamed Ali Ezz El DinDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Mohamed Osama AlorabiDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.ORCID 0000-0002-3706-6332

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPleural mesothelioma (PM) is a rare aggressive cancer linked to asbestos exposure, with limited treatment options, especially in low-resource settings. While immune checkpoint inhibitors show promise, access remains limited in many countries.

methodsThis prospective study was conducted at Ain Shams University Hospital from November 2022 to December 2024. 42 patients with unresectable PM and no progression after 4-6 cycles of platinum-pemetrexed chemotherapy were randomized 1:1 to receive switch-maintenance gemcitabine (1000 mg/m

resultsMaintenance gemcitabine significantly improved PFS in unresectable PM (8.9 vs. 5.2 months,

conclusionMaintenance gemcitabine significantly improved PFS and was well tolerated, offering a practical and affordable treatment option for PM. CLINICAL

trial registrationwww.clinicaltrials.gov identifier is NCT05660616.

Indexed as

Antimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineMesotheliomaMesothelioma, MalignantPleural NeoplasmsAdultAgedFemaleGemcitabineHumansMaintenance ChemotherapyMaleMiddle AgedPemetrexedProgression-Free SurvivalAntimetabolites, AntineoplasticDeoxycytidineGemcitabinePemetrexedgemcitabinemaintenance therapyoverall survivalplatinum-pemetrexedPleural mesotheliomaprogression-free survivalresource-limited settings

Identifiers

PMID40501447
PMCPMC12239787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.